Bayer HealthCare und Regeneron planen Start einer Phase-III-Studie im zweiten Halbjahr 2007

29-03-2007

Positive Ergebnisse zeigt die vorläufige Zwischenanalyse einer Phase-II-Studie mit VEGF Trap-Eye. Die Studie untersucht VEGF Trap-Eye zur Behandlung einer Form der feuchten altersbedingten Makula-Degeneration (AMD). Die Patienten wurden in fünf Gruppen unterteilt und erhielten verschiedene ...

more

22-01-2007

DelSiTech Ltd and Bayer Innovation GmbH announced that they entered into a license agreement. The agreement enables Bayer the exclusive rights to use the unique and proprietary DelSiTech ® drug delivery technology for fiber applications in the fields of wound care and certain other ...

more

Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications

10-11-2006

After extensive discussions with the regulatory authorities in the U.S. and Europe, Bayer and Ortho-McNeil, Inc. have determined the final design of the phase III study program for the oral anticoagulant rivaroxaban in two chronic indications: Stroke prevention in atrial fibrillation (SPAF) ...

more

21-07-2006

CuraGen Corporation has been informed by Bayer Pharmaceuticals Corporation that Bayer plans to license BAY 76-7171 (formerly CT052). BAY 76-7171 was discovered under an ongoing metabolic disorder collaboration between CuraGen and Bayer aimed at identifying and developing potential small ...

more

03-07-2006

Cellectis SA and Bayer BioScience NV announced that they have signed an agreement under which Bayer CropScience will have access to Cellectis' proprietary custom-made Meganuclease technology for use in plant research and to develop products for use in agriculture. Financial terms and ...

more

26-06-2006

Bayer Innovation GmbH and greenovation Biotech GmbH have concluded a licensing and service agreement in the field of protein glycosylation in plants. This was announced by the companies today. The terms of the agreement will not be disclosed. In this context, glycosylation is a process by ...

more

02-11-2005

Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. announced the selection of Nexavar® (sorafenib tosylate) Tablets as the global trade name for sorafenib, the oral investigational drug under FDA review for the treatment of advanced renal cell carcinoma (RCC), or kidney ...

more

Substantial boost planned for the Health Care business:

21-02-2002

Leverkusen - Bayer AG and Aventis have signed a non-binding letter of intent to establish a joint venture for biological products. The companies plan to combine Bayer's Biological Products Business Group with the Aventis subsidiary Aventis Behring, with Bayer owning a substantial majority ...

more

Bayer and GlaxoSmithKline Announce EMEA Acceptance of Regulatory Filing for Vardenafil

04-02-2002

Leverkusen/London ? Bayer AG and GlaxoSmithKline plc (GSK) today announce that the European Medicinal Evaluation Agency (EMEA) has accepted the filing of a the marketing authorization application for vardenafil for the treatment of erectile dysfunction (ED). Bayer submitted the registration ...

more